Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | THPO | P40225 | 2/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.76 |
| ▸ | GLA | P06280 | 1/20 | 0.76 |
| ▸ | EIF4E | P06730 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | TOP1 | P11387 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taribavirin SCHEMBL2619250 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL12758161 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL3307695 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL3307685 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL4967368 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL16330745 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL6981526 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL2631656 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL18735565 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL40670 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930093-B2 | Use of ribofuranose derivatives against inflammatory bowel diseases | VALEANT RESEARCH & DEVELOPMENT (US) | 2005-08-16 | — | — | US | claimed |
| US-20050153908-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND LTD. | 2005-07-14 | — | — | US | claimed |
| WO-2005004881-A1 | USE OF RIBOFURANOSE DERIVATIVES AGAINST INFLAMMATORY BOWEL DISEASES | ICN PHARMACEUTICALS SWITZERLAND LTD. (CH) | 2005-01-20 | — | — | WO | claimed |
| US-20050009768-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND AG | 2005-01-13 | — | — | US | claimed |
| US-20050009767-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND AG | 2005-01-13 | — | — | US | claimed |
| US-20050009766-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND LTD. | 2005-01-13 | — | — | US | claimed |
| US-20040077563-A1 | Methods of drug delivery to hepatocytes and treatment of flaviviridae infections | VALEANT RESEARCH & DEVELOPMENT | 2004-04-22 | — | — | US | claimed |
| EP-1313469-A1 | METHODS OF DRUG DELIVERY TO HEPATOCYTES AND TREATMENT OF FLAVIVIRIDAE INFECTIONS | Ribapharm, Inc. (US) | 2003-05-28 | — | — | EP | claimed |
| WO-2002015904-B1 | METHODS OF DRUG DELIVERY TO HEPATOCYTES AND TREATMENT OF FLAVIVIRIDAE INFECTIONS | ICN PHARMACEUTICALS (US) | 2002-07-04 | — | — | WO | claimed |
| WO-2002015904-A1 | METHODS OF DRUG DELIVERY TO HEPATOCYTES AND TREATMENT OF FLAVIVIRIDAE INFECTIONS | RIBAPHARM, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| US-7560436-B2 | Methods of treating gastrointestinal inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-04 | — | — | US | disclosed |
| US-6930093-B2 | Use of ribofuranose derivatives against inflammatory bowel diseases | VALEANT RESEARCH & DEVELOPMENT (US) | 2005-08-16 | — | — | US | disclosed |
| US-20050153908-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND LTD. | 2005-07-14 | — | — | US | disclosed |
| US-20050153907-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND LTD. | 2005-07-14 | — | — | US | disclosed |
| WO-2005004881-A1 | USE OF RIBOFURANOSE DERIVATIVES AGAINST INFLAMMATORY BOWEL DISEASES | ICN PHARMACEUTICALS SWITZERLAND LTD. (CH) | 2005-01-20 | — | — | WO | disclosed |
| US-20050009768-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND AG | 2005-01-13 | — | — | US | disclosed |
| US-20050009767-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND AG | 2005-01-13 | — | — | US | disclosed |
| US-20050009766-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND LTD. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009766-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | RNASE1, ATIC, SI | PNP 24/4885LMNA 1557/4885SMN1; SMN2 1606/4885 |
| US-20050153907-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | RNASE1, ATIC, SI | PNP 24/4885LMNA 1557/4885SMN1; SMN2 1606/4885 |
| US-20050009767-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | RNASE1, ATIC, SI | PNP 24/4885LMNA 1557/4885SMN1; SMN2 1606/4885 |
| US-20050153908-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | RNASE1, ATIC, SI | PNP 24/4885LMNA 1557/4885SMN1; SMN2 1606/4885 |
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | IFNG, IFNAR1, TNF | PNP 1714/4885LMNA 4303/4885SMN1; SMN2 4531/4885 |
| US-20050009768-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | RNASE1, ATIC, SI | PNP 24/4885LMNA 1557/4885SMN1; SMN2 1606/4885 |
| US-20040077563-A1 | Methods of drug delivery to hepatocytes and treatment of flaviviridae infections | HAVCR2, GOT1, SLC10A1 | PNP 107/4885LMNA 2167/4885SMN1; SMN2 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.